Incyte's stars align as new CEO strikes $2B Vega takeover for blood disorder asset.

{
  "signal_id": "f12dd627-b36a-49c5-8c03-c1b096165157",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-06-08T13:52:12+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "url": "https://www.biospace.com/business/incytes-stars-align-as-new-ceo-strikes-2b-vega-takeover-for-blood-disorder-asset",
    "title": "Incyte's stars align as new CEO strikes $2B Vega takeover for blood disorder asset.",
    "ticker": "NASDAQ:INCY",
    "excerpt": "Incyte's stars align as new CEO strikes $2B Vega takeover for blood disorder asset.\n\nJune 8, 2026 |\n\nIncyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has \"pipeline-in-a-product\" potential.\n\nIncyte is adding a star to its constellation of hematology assets with the acquisition of Vega Therapeutics for up to $2 billion.\n\nVega, a subsidiary of Star Therapeutics, will bring VGA039, a monocolonal antibody in Phase 3 development for the bleeding disorder von Willebrand disease (VWD).\n\nIncyte is paying Star $1.25 billion up front, plus $750 million in potential milestones. The deal is expected to close in the third quarter. Beyond Vega, Star has three other programs in Phase 3 development, according to the release.\n\nVGA039 was Star's lead program and recently secured the FDA's rare pediatric disease and breakthrough therapy designations in VWD. The ongoing trial, called VIVID-6, includes patients with all types of the disorder, even those with a more severe case.\n\nEarly data from just three patients presented in December 2024 showed a substantial reduction in annualized bleeding rate, matching currently approved treatments for VWD.\n\nVWD is the initial indication for the program, but Incyte believes the asset could have value in other bleeding disorders as well. The drug modulates Protein S and is thought to...",
    "summary": "Incyte Corporation acquired Vega Therapeutics, Inc. for $2B on Jun 8th '26.",
    "planning": false,
    "image_url": "https://static.biospace.com/dims4/default/baa29ef/2147483647/strip/true/crop/2059x1158+0+149/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F74%2F9e%2F0b4b0115493f9b707521c1eb4c62%2Fistock-892834918.jpg",
    "confidence": 0.4455,
    "published_at": "2026-06-08T13:52:12Z",
    "effective_date": "2026-06-08",
    "article_sentence": "Incyte is adding a star to its constellation of hematology assets with the acquisition of Vega Therapeutics for up to $2 billion.",
    "amount_normalized": 2000000000,
    "related_company_name": "Vega Therapeutics, Inc.",
    "related_company_domain": "vega-therapeutics.com"
  }
}

curl https://signals.autobound.ai/v1/signals/f12dd627-b36a-49c5-8c03-c1b096165157 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'